Home » Topics » BioWorld Science, Hematologic

BioWorld Science, Hematologic
RSS

Structure of new oral anticoagulant revealed by DuPont at recent congress

Sep. 8, 2000

Thrombin inhibitors and their prodrugs synthesized at AstraZeneca

Sep. 7, 2000

Teijin reports on new class of factor Xa inhibitors

Sep. 7, 2000

DuPont designs potent and selective factor Xa inhibitors with excellent PK profile

Sep. 7, 2000

Factor Xa inhibitors with anticoagulant and antithrombotic effects identified at Lilly

Sep. 6, 2000

New series of factor Xa inhibitors claimed by Aventis

Sep. 1, 2000

New series of factor Xa inhibitors reported by German lab

Aug. 31, 2000

Roxifiban inhibits platelet aggregation dose-dependently in CAD patients

Aug. 30, 2000

Safety and efficacy data reported on AstraZeneca's P2T receptor antagonist in PTCA

Aug. 30, 2000

Novel factor Xa inhibitors under development for thromboembolic disorders

Aug. 24, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...